|
1
|
Chow WH, Dong LM and Devesa SS:
Epidemiology and risk factors for kidney cancer. Nat Rev Urol.
7:245–257. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Volpe A and Patard JJ: Prognostic factors
in renal cell carcinoma. World J Urol. 28:319–327. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rathmell WK and Godley PA: Recent updates
in renal cell carcinoma. Curr Opin Oncol. 22:250–256. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Al-Ali BM, Ress AL, Gerger A and Pichler
M: MicroRNAs in renal cell carcinoma: Implications for
pathogenesis, diagnosis, prognosis and therapy. Anticancer Res.
32:3727–3732. 2012.PubMed/NCBI
|
|
5
|
Zisman A, Pantuck AJ, Wieder J, Chao DH,
Dorey F, Said JW, deKernion JB, Figlin RA and Belldegrun AS: Risk
group assessment and clinical outcome algorithm to predict the
natural history of patients with surgically resected renal cell
carcinoma. J Clin Oncol. 20:4559–4566. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rini BI, Campbell SC and Escudier B: Renal
cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Baughman JM, Nilsson R, Gohil VM, Arlow
DH, Gauhar Z and Mootha VK: A computational screen for regulators
of oxidative phosphorylation implicates SLIRP in mitochondrial RNA
homeostasis. PLoS Genet. 5:e10005902009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Seo M, Lee WH and Suk K: Identification of
novel cell migration-promoting genes by a functional genetic
screen. FASEB J. 24:464–478. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu Y, Clegg HV, Leslie PL, Di J, Tollini
LA, He Y, Kim TH, Jin A, Graves LM, Zheng J and Zhang Y: CHCHD2
inhibits apoptosis by interacting with Bcl-x L to regulate Bax
activation. Cell Death Differ. 22:1035–1046. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Guinan P, Sobin LH, Algaba F, Badellino F,
Kameyama S, MacLennan G and Novick A: TNM staging of renal cell
carcinoma: Workgroup No 3. Union International Contre le Cancer
(UICC) and the American Joint Committee on Cancer (AJCC). Cancer.
80:992–993. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sobin LH and Fleming ID: TNM
classification of malignant tumors, fifth edition (1997) union
internationale contre le cancer and the American joint committee on
cancer. Cancer. 80:1803–1804. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Baumann P, Cremers N, Kroese F, Orend G,
Chiquet-Ehrismann R, Uede T, Yagita H and Sleeman JP: CD24
expression causes the acquisition of multiple cellular properties
associated with tumor growth and metastasis. Cancer Res.
65:10783–10793. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chu YW, Yang PC, Yang SC, Shyu YC, Hendrix
MJ, Wu R and Wu CW: Selection of invasive and metastatic
subpopulations from a human lung adenocarcinoma cell line. Am J
Respir Cell Mol Biol. 17:353–360. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wachsberger P, Burd R and Dicker AP: Tumor
response to ionizing radiation combined with antiangiogenesis or
vascular targeting agents: Exploring mechanisms of interaction.
Clin Cancer Res. 9:1957–1971. 2003.PubMed/NCBI
|
|
15
|
Bai J, Mei PJ, Liu H, Li C, Li W, Wu YP,
Yu ZQ and Zheng JN: BRG1 expression is increased in human glioma
and controls glioma cell proliferation, migration and invasion in
vitro. J Cancer Res Clin Oncol. 138:991–998. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kargiotis O, Chetty C, Gondi CS, Tsung AJ,
Dinh DH, Gujrati M, Lakka SS, Kyritsis AP and Rao JS:
Adenovirus-mediated transfer of siRNA against MMP-2 mRNA results in
impaired invasion and tumor-induced angiogenesis, induces apoptosis
in vitro and inhibits tumor growth in vivo in glioblastoma.
Oncogene. 27:4830–4840. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Badiga AV, Chetty C, Kesanakurti D, Are D,
Gujrati M, Klopfenstein JD, Dinh DH and Rao JS: MMP-2 siRNA
inhibits radiation-enhanced invasiveness in glioma cells. PLoS One.
6:e206142011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bergers G and Benjamin LE: Tumorigenesis
and the angiogenic switch. Nat Rev Cancer. 3:401–410. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dvorak HF: Vascular permeability
factor/vascular endothelial growth factor: A critical cytokine in
tumor angiogenesis and a potential target for diagnosis and
therapy. J Clin Oncol. 20:4368–4380. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ferrara N: Vascular endothelial growth
factor: Basic science and clinical progress. Endocr Rev.
25:581–611. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lucio-Eterovic AK, Piao Y and de Groot JF:
Mediators of glioblastoma resistance and invasion during
antivascular endothelial growth factor therapy. Clin Cancer Res.
15:4589–4599. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Aras S, Pak O, Sommer N, Finley R Jr,
Hüttemann M, Weissmann N and Grossman LI: Oxygen-dependent
expression of cytochrome c oxidase subunit 4-2 gene expression is
mediated by transcription factors RBPJ, CXXC5 and CHCHD2. Nucleic
Acids Res. 41:2255–2266. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Feyeux M, Bourgois-Rocha F, Redfern A,
Giles P, Lefort N, Aubert S, Bonnefond C, Bugi A, Ruiz M, Deglon N,
et al: Early transcriptional changes linked to naturally occurring
Huntington's disease mutations in neural derivatives of human
embryonic stem cells. Hum Mol Genet. 21:3883–3895. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Aras S, Bai M, Lee I, Springett R,
Hüttemann M and Grossman LI: MNRR1 (formerly CHCHD2) is a
bi-organellar regulator of mitochondrial metabolism. Mitochondrion.
43–51. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kaltenbach LS, Romero E, Becklin RR,
Chettier R, Bell R, Phansalkar A, Strand A, Torcassi C, Savage J,
Hurlburt A, et al: Huntingtin interacting proteins are genetic
modifiers of neurodegeneration. PLoS Genet. 3:e822007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hannon GJ: RNA interference. Nature.
418:244–251. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Elbashir SM, Harborth J, Weber K and
Tuschl T: Analysis of gene function in somatic mammalian cells
using small interfering RNAs. Methods. 26:199–213. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rundhaug JE: Matrix metalloproteinases and
angiogenesis. J Cell Mol Med. 9:267–285. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Deryugina EI and Quigley JP: Matrix
metalloproteinases and tumor metastasis. Cancer Metastasis Rev.
25:9–34. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Folkman J: What is the evidence that
tumors are angiogenesis dependent? J Natl Cancer Inst. 82:4–6.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fidler IJ: Angiogenesis and cancer
metastasis. Cancer J. 6 Suppl 2:S134–S141. 2000.PubMed/NCBI
|
|
32
|
Jacobsen J, Rasmuson T, Grankvist K and
Ljungberg B: Vascular endothelial growth factor as prognostic
factor in renal cell carcinoma. J Urol. 163:343–347. 2000.
View Article : Google Scholar : PubMed/NCBI
|
